Kamada (NASDAQ:KMDA) Stock Price Crosses Below Two Hundred Day Moving Average - Time to Sell?

Key Points

• Kamada shares fell below their 200-day moving average, trading as low as $7.59 versus the $7.85 average, and last traded at $7.69.
• Analysts remain broadly positive: four analysts rate the stock a Buy, with an average price target of $13.50 compared with the current price.
• Kamada exceeded quarterly expectations, reporting $0.16 in EPS and $54.92 million in revenue, but cut its annual dividend to $0.17 per share from $0.25.

Kamada Ltd. (NASDAQ:KMDA - Get Free Report)'s stock price passed below its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $7.85 and traded as low as $7.59. Kamada shares last traded at $7.69, with a volume of 87,325 shares traded.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on KMDA shares. UBS Group reaffirmed a "buy" rating and set a $15.00 price objective on shares of Kamada in a research report on Friday, September 18th. Wall Street Zen raised Kamada from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 15th. Benchmark reaffirmed a "buy" rating on shares of Kamada in a research report on Tuesday, July 21st. William Blair set a $15.00 price target on shares of Kamada in a research note on Tuesday, July 21st. Finally, Weiss Ratings raised shares of Kamada from a "buy (b-)" rating to a "buy (b)" rating in a report on Friday. Four investment analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, Kamada has an average rating of "Buy" and an average price target of $13.50.

Kamada Stock Down 1.9%

The stock has a market capitalization of $442.25 million, a price-to-earnings ratio of 20.24, a price-to-earnings-growth ratio of 0.66 and a beta of 0.89. The stock's 50-day simple moving average is $8.12 and its 200 day simple moving average is $7.85.

Kamada (NASDAQ:KMDA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.05. The firm had revenue of $54.92 million during the quarter, compared to the consensus estimate of $50.84 million. Kamada had a return on equity of 8.37% and a net margin of 11.60%. As a group, equities research analysts anticipate that Kamada Ltd. will post 0.48 earnings per share for the current year.

Kamada Cuts Dividend

The company also recently disclosed an annual dividend, which was paid on Thursday, September 17th. Shareholders of record on Thursday, August 27th were issued a dividend of $0.17 per share. The ex-dividend date of this dividend was Thursday, August 27th. This represents a yield of 206.0%. This is a negative change from Kamada's previous annual dividend of $0.25. Kamada's dividend payout ratio (DPR) is currently 34.21%.

Institutional Investors Weigh In On Kamada

A hedge fund recently raised its position in Kamada stock. Aristides Capital LLC boosted its position in shares of Kamada Ltd. (NASDAQ:KMDA - Free Report) by 4.5% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 34,491 shares of the biotechnology company's stock after purchasing an additional 1,476 shares during the quarter. Aristides Capital LLC owned about 0.06% of Kamada worth $288,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 20.38% of the company's stock.

Kamada Company Profile

Kamada Ltd. is an Israeli biopharmaceutical company focused on the development, manufacturing and commercialization of plasma-derived therapies. The company's products are designed to treat rare diseases, immune deficiencies and other serious medical conditions, with an emphasis on specialty biologic medicines and immunoglobulin-based treatments.

Kamada's portfolio includes Glassia, an alpha-1 antitrypsin augmentation therapy for patients with alpha-1 antitrypsin deficiency; KEDRAB, a human rabies immune globulin used for post-exposure prophylaxis; WINRHO SDF, an immune globulin product; and CYTOGAM, a cytomegalovirus immune globulin.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.